GB201106743D0 - Novel compounds - Google Patents
Novel compoundsInfo
- Publication number
- GB201106743D0 GB201106743D0 GB201106743A GB201106743A GB201106743D0 GB 201106743 D0 GB201106743 D0 GB 201106743D0 GB 201106743 A GB201106743 A GB 201106743A GB 201106743 A GB201106743 A GB 201106743A GB 201106743 D0 GB201106743 D0 GB 201106743D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- novel compounds
- compounds
- therapy
- pharmaceutical compositions
- compositions containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000147 tetrahydroquinolinyl group Chemical class N1(CCCC2=CC=CC=C12)* 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201106743A GB201106743D0 (en) | 2011-04-21 | 2011-04-21 | Novel compounds |
| KR1020137030972A KR101896599B1 (ko) | 2011-04-21 | 2012-04-19 | 브로모도메인 억제제로서 유용한 테트라하이드로퀴놀린 유도체 |
| EP12716378.0A EP2699550B1 (en) | 2011-04-21 | 2012-04-19 | Tetrahydroquinoline derivatives useful as bromodomain inhibitors |
| CA2832763A CA2832763C (en) | 2011-04-21 | 2012-04-19 | Tetrahydroquinoline derivatives useful as bromodomain inhibitors |
| BR112013026834A BR112013026834A2 (pt) | 2011-04-21 | 2012-04-19 | composto, composição farmacêutica, produto farmacêutico de combinação, uso de um composto, e, método para tratar doenças ou condições e para inibir um bromodomínio |
| CN201280029939.XA CN103619820B (zh) | 2011-04-21 | 2012-04-19 | 可用作溴区结构域抑制剂的四氢喹啉衍生物 |
| EA201391285A EA022341B1 (ru) | 2011-04-21 | 2012-04-19 | Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена |
| PCT/EP2012/057111 WO2012143413A1 (en) | 2011-04-21 | 2012-04-19 | Tetrahydroquinoline derivatives useful as bromodomain inhibitors |
| ES12716378.0T ES2544302T3 (es) | 2011-04-21 | 2012-04-19 | Derivados de tetrahidroquinolina útiles como inhibidores de bromodominio |
| MX2013012190A MX338515B (es) | 2011-04-21 | 2012-04-19 | Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio. |
| US14/111,580 US9029395B2 (en) | 2011-04-21 | 2012-04-19 | Tetrahydroquinoline derivatives useful as bromodomain inhibitors |
| AU2012244759A AU2012244759B2 (en) | 2011-04-21 | 2012-04-19 | Tetrahydroquinoline derivatives useful as bromodomain inhibitors |
| SG2013076146A SG194469A1 (en) | 2011-04-21 | 2012-04-19 | Tetrahydroquinoline derivatives useful as bromodomain inhibitors |
| JP2014505610A JP5840763B2 (ja) | 2011-04-21 | 2012-04-19 | ブロモドメイン阻害剤として有用なテトラヒドロキノリン誘導体 |
| IL228707A IL228707A (en) | 2011-04-21 | 2013-10-03 | Tetrahydroquinoline history used as bromodomain inhibitors |
| ZA2013/07645A ZA201307645B (en) | 2011-04-21 | 2013-10-14 | Tetrahydroquinoline derivatives useful as bromodomain inhibitors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201106743A GB201106743D0 (en) | 2011-04-21 | 2011-04-21 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201106743D0 true GB201106743D0 (en) | 2011-06-01 |
Family
ID=44147335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB201106743A Ceased GB201106743D0 (en) | 2011-04-21 | 2011-04-21 | Novel compounds |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9029395B2 (enExample) |
| EP (1) | EP2699550B1 (enExample) |
| JP (1) | JP5840763B2 (enExample) |
| KR (1) | KR101896599B1 (enExample) |
| CN (1) | CN103619820B (enExample) |
| AU (1) | AU2012244759B2 (enExample) |
| BR (1) | BR112013026834A2 (enExample) |
| CA (1) | CA2832763C (enExample) |
| EA (1) | EA022341B1 (enExample) |
| ES (1) | ES2544302T3 (enExample) |
| GB (1) | GB201106743D0 (enExample) |
| IL (1) | IL228707A (enExample) |
| MX (1) | MX338515B (enExample) |
| SG (1) | SG194469A1 (enExample) |
| WO (1) | WO2012143413A1 (enExample) |
| ZA (1) | ZA201307645B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201107325D0 (en) | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| AU2013365926B9 (en) | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| NZ710765A (en) * | 2013-03-14 | 2020-05-29 | Glaxosmithkline Ip No 2 Ltd | 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors |
| SG11201506924YA (en) | 2013-03-15 | 2015-09-29 | Incyte Corp | Tricyclic heterocycles as bet protein inhibitors |
| CN105492439B (zh) | 2013-06-21 | 2019-11-22 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的取代的双环化合物 |
| SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
| AR096837A1 (es) | 2013-07-08 | 2016-02-03 | Incyte Corp | Heterociclos tricíclicos como inhibidores de proteínas bet |
| WO2015015318A2 (en) | 2013-07-31 | 2015-02-05 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| EP3105232B1 (en) * | 2014-02-10 | 2019-08-28 | Concert Pharmaceuticals Inc. | Substituted triazolobenzodiazepines |
| UA119870C2 (uk) | 2014-04-23 | 2019-08-27 | Інсайт Корпорейшн | 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET |
| AU2015295405B2 (en) * | 2014-08-01 | 2020-04-09 | Nuevolution A/S | Compounds active towards bromodomains |
| JP6531167B2 (ja) | 2014-09-12 | 2019-06-12 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | ブロモドメイン阻害剤としてのテトラヒドロキノリン誘導体 |
| US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| EP3201199A1 (en) * | 2014-10-02 | 2017-08-09 | Glaxosmithkline Intellectual Property (No. 2) Limited | Compound |
| EP3227281A4 (en) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| HK1246273B (en) | 2014-12-01 | 2019-12-06 | 恒翼生物医药(上海)股份有限公司 | Substituted pyridines as bromodomain inhibitors |
| US10292968B2 (en) | 2014-12-11 | 2019-05-21 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
| CA2966450A1 (en) | 2014-12-17 | 2016-06-23 | Olesya KHARENKO | Inhibitors of bromodomains |
| GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
| IL263824B2 (en) | 2016-06-20 | 2023-10-01 | Incyte Corp | Crystals in solid form in the presence of an inhibitor |
| ES2937307T3 (es) | 2016-07-26 | 2023-03-27 | Univ Southern California | Inhibición selectiva del bromodominio del BDF1 fúngico |
| WO2018111805A1 (en) | 2016-12-13 | 2018-06-21 | St. Jude Children's Research Hospital | Tetrahydroquinoline-based bromodomain inhibitors |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| JP4641526B2 (ja) | 2003-11-03 | 2011-03-02 | グラクソ グループ リミテッド | 流体分配デバイス |
| JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Ｂｒｄ２ブロモドメイン結合剤 |
| EP2239264A4 (en) | 2007-12-28 | 2012-01-11 | Mitsubishi Tanabe Pharma Corp | ANTITUMORAL MEDIUM |
| US8791090B2 (en) * | 2009-03-31 | 2014-07-29 | Kowa Company, Ltd. | Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient |
| GB0919431D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| EP2955524A3 (en) * | 2009-11-05 | 2016-03-23 | GlaxoSmithKline LLC | Novel process |
| GB201106750D0 (en) * | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201107325D0 (en) * | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| WO2013033270A2 (en) * | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same |
-
2011
- 2011-04-21 GB GB201106743A patent/GB201106743D0/en not_active Ceased
-
2012
- 2012-04-19 ES ES12716378.0T patent/ES2544302T3/es active Active
- 2012-04-19 SG SG2013076146A patent/SG194469A1/en unknown
- 2012-04-19 CN CN201280029939.XA patent/CN103619820B/zh not_active Expired - Fee Related
- 2012-04-19 MX MX2013012190A patent/MX338515B/es active IP Right Grant
- 2012-04-19 AU AU2012244759A patent/AU2012244759B2/en not_active Ceased
- 2012-04-19 EA EA201391285A patent/EA022341B1/ru not_active IP Right Cessation
- 2012-04-19 EP EP12716378.0A patent/EP2699550B1/en active Active
- 2012-04-19 JP JP2014505610A patent/JP5840763B2/ja not_active Expired - Fee Related
- 2012-04-19 CA CA2832763A patent/CA2832763C/en not_active Expired - Fee Related
- 2012-04-19 KR KR1020137030972A patent/KR101896599B1/ko not_active Expired - Fee Related
- 2012-04-19 US US14/111,580 patent/US9029395B2/en not_active Expired - Fee Related
- 2012-04-19 BR BR112013026834A patent/BR112013026834A2/pt not_active Application Discontinuation
- 2012-04-19 WO PCT/EP2012/057111 patent/WO2012143413A1/en not_active Ceased
-
2013
- 2013-10-03 IL IL228707A patent/IL228707A/en active IP Right Grant
- 2013-10-14 ZA ZA2013/07645A patent/ZA201307645B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2699550A1 (en) | 2014-02-26 |
| US9029395B2 (en) | 2015-05-12 |
| KR20140025484A (ko) | 2014-03-04 |
| CA2832763C (en) | 2019-09-24 |
| US20140039006A1 (en) | 2014-02-06 |
| MX338515B (es) | 2016-04-20 |
| AU2012244759B2 (en) | 2016-03-03 |
| JP5840763B2 (ja) | 2016-01-06 |
| CN103619820B (zh) | 2015-08-19 |
| BR112013026834A2 (pt) | 2016-12-27 |
| IL228707A0 (en) | 2013-12-31 |
| WO2012143413A1 (en) | 2012-10-26 |
| EA201391285A1 (ru) | 2014-04-30 |
| SG194469A1 (en) | 2013-12-30 |
| MX2013012190A (es) | 2014-01-31 |
| KR101896599B1 (ko) | 2018-09-07 |
| ES2544302T3 (es) | 2015-08-28 |
| IL228707A (en) | 2016-09-29 |
| EP2699550B1 (en) | 2015-06-10 |
| ZA201307645B (en) | 2015-04-29 |
| EA022341B1 (ru) | 2015-12-30 |
| CA2832763A1 (en) | 2012-10-26 |
| AU2012244759A1 (en) | 2013-10-31 |
| JP2014511891A (ja) | 2014-05-19 |
| CN103619820A (zh) | 2014-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201106743D0 (en) | Novel compounds | |
| GB201106750D0 (en) | Novel compounds | |
| MX2014009757A (es) | Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| PH12013500955A1 (en) | Spiro-oxindole mdm2 antagonists | |
| MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| IN2014CN00568A (enExample) | ||
| IN2014MN02598A (enExample) | ||
| MX346375B (es) | Antagonistas de espiro-oxindol de mdm2. | |
| IL237839A0 (en) | History of hydropyrrolopyrrole, their preparation and pharmaceutical preparations containing them | |
| MX349004B (es) | Nuevos compuestos. | |
| EA201400771A1 (ru) | Новые производные азетидина, фармацевтические композиции и их применение | |
| IN2014DN06104A (enExample) | ||
| IL235414A (en) | The history of pyrolotriazinone, their preparation and their pharmaceutical preparations | |
| PH12015501609A1 (en) | Phenicol antibacterials | |
| IL232577A0 (en) | The history of morpholinylbenzotriazine, their preparation and pharmaceutical preparations containing them | |
| MX357284B (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
| MX2012010127A (es) | Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos. | |
| PH12017500348A1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
| ZA201400646B (en) | Topical ophthalmological pharmaceutical composition containing regorafenib | |
| IL230219B (en) | History of dihydropyrazole, their preparation and pharmaceutical preparations containing them | |
| ZA201306905B (en) | Novel octahydrothienoquinonline derivative,pharmaceutical composition comprising derivative, and use of these | |
| MX2014004210A (es) | Derivados de 2-oxo-piperidinilo. | |
| ZA201505196B (en) | Topical ophthalmological pharmaceutical composition containing regorafenib | |
| MX367773B (es) | Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos. | |
| IL238826A0 (en) | History of imidazole - piperidinyl, their preparation and pharmaceutical preparations containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |